3,4-Diaminopyridine
120px | |
Systematic (IUPAC) name | |
---|---|
3,4-Diaminopyridine | |
Clinical data | |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 30% [1],[2] |
Identifiers | |
CAS Number | 54-96-6 |
PubChem | CID 5918 |
ChemSpider | 5705 |
Chemical data | |
Formula | C5H7N3 |
Molar mass | 109.13[[Script error: No such module "String".]] |
Script error: No such module "collapsible list". |
3,4-Diaminopyridine is an organic compound with the formula C5H3N(NH2)2. It is formally derived from pyridine by substitution of the 3 and 4 positions with an amino group.
Applications
3,4-Diaminopyridine experimental drug for the treatment of Lambert-Eaton Syndrome. In Lambert-Eaton Syndrome, acetylcholine release is inhibited as antibodies meant to target characteristic cancers target Ca2+ channels on the prejunctional membrane instead. 3,4-Diaminopyridine works by blocking potassium channel efflux in nerve terminals so that action potential duration is increased. Ca2+ channels can then be open for longer time and allow greater acetylcholine release to stimulate muscle at end plate. It is also used to treat many of the Congenital Myasthenic Syndromes.
This compound has also been proposed for the treatment of multiple sclerosis.[3]
See also
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
This pharmacology-related article is a stub. You can help ssf by expanding it. |
- ↑ AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. (2001). "Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthena gravis or Lambert-Eaton myasthenic syndrome: summary statement". Muscle Nerve. 24 (9): 1236–1238. doi:10.1002/mus.1139. PMID 11494280.
- ↑ Lundh H, Nilsson O, Rosen I, Johansson S. (1993). "Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome". Acta Neurol Scand. 88 (2): 136–140. doi:10.1111/j.1600-0404.1993.tb04205.x. PMID 8213058.
- ↑ Judge S, Bever C (2006). "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment". Pharmacol. Ther. 111 (1): 224–59. doi:10.1016/j.pharmthera.2005.10.006. PMID 16472864.
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Articles containing unverified chemical infoboxes
- Potassium channel blockers
- Pyridines
- Pharmacology stubs
- 2Fix
- CS1 maint: Multiple names: authors list